ERBB3 and neoplasm: 1A5-3D4 is an anti-HER3 antibody that in combination with trastuzumab has shown tumor size reduction in preclinical gastric cancer xenografts.[139] 9F7-F11 is an anti-HER3 antibody that induces apoptosis in cell lines by increasing HER3 ubiquitination and degradation through JNK-dependent ITCH/AIP4 activation.